Whey vs Plant vs Yeast Protein: What the Human Evidence Supports

Confidence: high in the category and allergy distinctions; low-to-moderate in precise efficacy rankings after strict funding screening. Lack of independent proof is not proof that an ingredient is ineffective.

Introduction

The useful question is not simply which name wins. It is: which specific product supplies an appropriate amount of protein, fits the person's diet, and has evidence relevant to the intended outcome?

The three categories are not equally uniform. Whey is a family of milk proteins. “Plant protein” covers many different crops. “Yeast protein” may describe whole inactivated yeast, a concentrated biomass ingredient, an isolate or an extract with a very different composition. Equal scoop sizes may therefore contain different amounts of actual protein.

This comparison excludes manufacturer-, seller- and industry-supported outcome evidence from its independent efficacy verdict, including donated study ingredients. Commercial trials are described for context and to show where claims come from. Government or university affiliation alone does not pass this screen, and a review's independence does not establish that of the trials it pools.

Table of contents

1. At-a-glance comparison
2. Evidence and funding summary
3. Types and forms
4. Protein quality and mechanisms
5. Benefits by claim
6. What works and what does not follow
7. Risks interactions and who needs advice
8. Doses studied and fair comparisons
9. Animal evidence and surrogate outcomes
10. Money countries and backers
11. Source-credibility scorecard
12. Regulatory context
13. FAQ
14. Sources and update record

At-a-glance comparison

The table describes categories, not a ranking of brands or a claim that every member has been tested.

Evidence and funding summary

There is deliberately no pooled “muscle gained” bar chart here. Combining different populations, exercise programmes, comparators and follow-up durations would create a misleading impression of a controlled three-way experiment.

Types and forms

Whey: concentrate isolate hydrolysate native and clear

Concentrate and isolate describe purification characteristics. Hydrolysate describes protein broken into smaller peptides; it can begin with different whey ingredients. Native whey describes direct separation from milk. Clear whey is a clear or juice-style formulation, often based on isolate or hydrolysate. These descriptions overlap.

Arla's ingredient pages market isolates for both clear and milky applications and a hydrolysate for clear sparkling drinks. These seller materials establish formulation possibilities only. They do not establish clinical superiority or dairy-free status. C7, C8

Plant: specify the ingredient

Soy, pea, rice, hemp, pumpkin and blended powders should not be treated as a single intervention. A blend can change amino-acid balance, but its name does not specify the ratio, digestibility or amount of protein in the final serving. A whole-food plant-based diet is also different from a powder added to an omnivorous diet.

Yeast: biomass is not every fermented protein

A concentrated yeast-biomass protein is distinct from nutritional yeast flakes, a salty yeast extract, a milligram-dose fermentate and a live probiotic such as Saccharomyces boulardii. Mycoprotein made from filamentous fungi is another category.

Precision fermentation can use a microorganism to make a particular protein. Health Canada's assessment of yeast-produced beta-lactoglobulin illustrates why the finished protein's identity matters: it remains a milk-allergen concern. A fermentation process is not evidence that the output belongs in the yeast-biomass category or is safe for milk allergy. C9

Protein quality and mechanisms

All three can contribute amino acids, but the quantities and relative amino-acid profiles depend on the ingredient. “Contains all essential amino acids,” “high leucine” and “high DIAAS” answer different questions.

Protein-quality scores assess amino-acid adequacy and digestibility against defined reference patterns. They are not direct measurements of strength, sustained muscle growth or better health. FAO's framework permits non-human digestibility methods when appropriate, so an animal-derived score should be labelled, not misrepresented as a human trial. C10

Useful comparisons keep the denominator constant: grams of actual protein rather than grams of flavoured powder, and amino acids per the same quantity. Matching protein, matching leucine and matching calories are different experimental choices. None by itself matches the entire diet, all amino acids or the training programme.

Benefits by claim

Protein adequacy

A suitable product can help fill a dietary protein shortfall. Whether there is a shortfall must be assessed from the whole diet and individual needs. The nutritional role of protein does not make a powder necessary. EU-authorized muscle-growth/maintenance claims apply to qualifying protein foods, not a special benefit exclusive to whey, plants or yeast. C11

Muscle growth and strength

The evidence does not support saying either “all proteins are identical” or “only whey works.” Independent evidence is thinner than the overall literature suggests once sponsor funding and product donations are screened.

The pea pilot and grant-supported soy trial are compatible with similar observed outcomes in their specific settings, but neither establishes universal equivalence. The independently eligible yeast outcome evidence is substantially less developed in the material located for this audit. That is a reason for more cautious claims about yeast, not proof that its protein cannot be used nutritionally. C1, C2, C3, C4, C5, C6

Weight loss glucose and recovery

No independently established three-way winner was identified. A powder supplies energy; its practical effect depends on what it replaces and the overall diet. Short-lived changes in fullness, blood glucose, circulating amino acids or muscle protein synthesis cannot substitute for sustained weight change, better diabetes outcomes or improved functional recovery.

Ageing and sarcopenia

Sarcopenia involves clinical assessment of strength, function and muscle measures. A result in young volunteers cannot simply be applied to frail older adults. A sponsored older-adult yeast study or a mixed multi-ingredient whey formula cannot establish that one source alone treats this condition. The 2025 plant-versus-animal review did not include trials measuring sarcopenia itself as an outcome. C3, C5

Gastrointestinal tolerance

There is no dependable universal tolerability ranking from the evidence audited here. Lactose, fibre, residual cell-wall material, sweeteners and the rest of a product's formulation can matter. A “lighter” clear drink may be a sensory preference without proving less digestive disturbance. Laboratory fermentation or gas measurements do not establish symptoms in people.

What works and what does not follow

Risks interactions and who needs advice

Allergy comes before optimization

Ordinary whey remains milk protein in concentrate, isolate, hydrolysed and clear forms. Lower lactose does not remove a milk-protein allergy. Plant alternatives may contain soy or other allergens, and pea can trigger reactions in some people with peanut allergy. No category should be advertised as incapable of allergy. C12, C13

Lactose intolerance differs from milk allergy

Lactose intolerance concerns milk-sugar digestion. Isolate often has less lactose than concentrate, but a finished product still needs checking. Hydrolysis breaks protein into peptides; it does not, by definition, remove lactose. C7, C14

Yeast-specific RNA and purine checks

Residual nucleic acids depend on processing. US rules for a specified processed baker's-yeast protein require nucleic acid below 2% of dry weight; this specification must not be converted into a universal safe dose or a claim that every retail yeast ingredient meets it. People with gout, hyperuricemia or uric-acid stones need the actual product specification and appropriate advice. Whole dried yeast and a purified low-RNA isolate should not automatically be assigned the same purine content. C15

Medicines and clinical diets

For levothyroxine, check the exact powder and medicine instructions; soy-related food components, fibre and minerals can affect absorption. The prescribing information does not provide a universal interaction size for every protein powder. C16

For monoamine oxidase inhibitors, concentrated yeast extracts are a specific concern. The tranylcypromine label distinguishes those extracts from ordinary baker's/brewer's yeast; an unfamiliar concentrated product still needs a pharmacist's assessment. C17

Kidney disease, prescribed protein restrictions, significant illness, pregnancy, breastfeeding and children's nutrition require individualized assessment. Products may also add potassium, phosphorus, sodium, vitamins or herbs. Do not change prescribed medicines or disease management based on this comparison.

Contaminants

No class label determines a batch's safety. A meaningful test report specifies the product, lot, laboratory, date, analytes, methods, limits and actual results. A contaminant survey is not a test of every brand and batch, and a certification mark is not a muscle-growth claim. This comparison does not certify any product or repeat category-wide contamination percentages as personal risk estimates.

Doses studied and fair comparisons

There is no independently validated conversion chart saying a fixed gram amount of whey, plant and yeast protein will produce the same result in every person.

Some often-misread research quantities are:

• Banaszek's pea/whey pilot used approximately 24 g protein twice daily, not 24 g for the whole day C1
• Lynch compared 26 g soy protein with 19 g whey protein daily, approximately leucine-matched; those are not equal protein doses C2
• Briskey's commercial yeast trial used 40 g supplement per day divided into two 20 g servings, not 40 g twice daily C4
• Bai's commercial older-adult trial used 20 g powder per day, supplying about 15–16 g protein C5

These quantities describe research, not recommended intake. A study testing one dose does not establish a minimum effective amount. A short-term MPS experiment does not establish an absorption ceiling. Food protein, body size, total energy, exercise, age and health all affect how a protocol should be interpreted.

For shopping comparisons, calculate price per the same amount of actual protein, then consider formulation, tolerance and testing. No current price ranking is claimed here because no equivalent products and batches were priced for this review.

Animal evidence and surrogate outcomes

Animal growth, cell signalling and simulated digestion were excluded as proof of human clinical efficacy. Composition and digestibility methods can still describe an ingredient when their limits are explicit. Acute MPS, whole-body IAAO and long-term hypertrophy are not interchangeable endpoints. The 2026 yeast preprint performed a specified noninferiority analysis using a 20% margin on acute oxidation. This is more than an ordinary null-difference test, but its result does not establish equivalence for muscle growth; IAAO must not be labelled direct muscle-biopsy MPS. C6, C10

Money countries and backers

Each category has sellers with a commercial stake. Dairy firms, crop-protein suppliers and yeast companies all benefit from favourable results. A funded null result can also be commercially useful. The same funding rule applies regardless of which ingredient wins.

The figure maps selected documented study relationships rather than implying that an entire category has a single owner. Company materials may establish corporate identity or ingredient processing; they do not supply independent efficacy evidence.

The TiFN sponsor relationship is explicit in the pea trial, rather than merely “industry-adjacent.” C18 Angel's nutrition-fund administration is documented on its own site. C19 These relationships show who financed the work; they do not establish misconduct.

Ownership examples are limited to verified disclosures in the companion audits. Arla Foods Ingredients identifies Arla Foods as its owner and Denmark as its base; Lesaffre describes family ownership in France. The precise ownership of every retail protein brand is outside this comparison. Ingredient origin, factory location and the country where a trial was run must not be conflated. C20, C21

Source-credibility scorecard

Tier and grade describe independence and incentives, not whether an individual measurement is true. Tier 1 is independently funded/no identified relevant stake; Tier 2 indirect ties; Tier 3 an interested party; Tier 4 maker/seller support. Unresolved information remains unknown.

FDA receives appropriations and legally restricted industry user fees; no protein-company sponsorship of these guidance pages is alleged. C24 Public agencies have accountability incentives but can face policy and institutional pressures. Researchers face novelty, publication and grant incentives. Industry disclosure is not inherently dishonest; the strict exclusion makes the verdict's source dependence visible. Relevant trials remain concentrated in a few countries and do not represent every population or formulation.

Regulatory context

FDA does not pre-approve US dietary supplements for safety or effectiveness. Ingredient specifications, facility registration and an agency's response to a particular food notification are not clinical endorsements. C15, C22

In India, the FSSAI regulatory route depends on the actual product category and ingredients. Overseas authorization cannot simply be treated as permission for the same formulation in India. The official portal is the starting point for verification; this comparison does not certify a retail product's compliance. C23

FAQ

Which one should I choose?

Start with whether extra protein is needed, then exclude incompatible allergens and assess the full product. Dietary preference, tolerability, cost per actual protein amount and test documentation can make one option more practical without making it clinically superior for everyone.

Is yeast protein just another plant protein?

It is fungal, not plant-derived. It may be a non-animal option, but keeping it separate prevents evidence from soy or pea being incorrectly attributed to yeast.

Is clear whey a fourth protein category?

No. It is a formulation within whey. Compare its actual ingredient and label rather than assigning an extra physiological benefit to a clear appearance. C7, C8

Are all three “complete”?

That word is too imprecise for a clinical ranking. Check amino-acid amounts, digestibility and actual protein content, and distinguish ingredient composition from outcomes in people. C10

Does the thinner independent yeast evidence mean it cannot work?

No. It means independent confirmation of particular benefits, doses and comparisons is missing from this audit. The honest conclusion is a research gap, not a verdict of zero nutritional value.

Can I mix them?

A mixed product is a new formulation with its own composition and allergen profile. Evidence for one ingredient does not automatically establish the mixture's outcome or its optimal ratio.

Sources and update record

Evidence checked / research update prepared: 1 October 2026. No completed clinical review or named clinical reviewer is asserted by this draft. This is a targeted evidence and funding audit, not a registered systematic review. No product purchase, batch certification or brand-price comparison was performed.

Companion ingredient articles: Whey protein, Plant protein, Yeast protein. This comparison is prepared for coordinated release with their corrected versions.

Source index

• C1 — Banaszek 2019
• C2 — Lynch 2020
• C3 — Reid-McCann 2025
• C4 — Briskey 2024
• C5 — Bai 2026
• C6 — Barsky 2026 preprint v1
• C7 — Arla whey isolate applications
• C8 — Arla hydrolysate for clear drinks
• C9 — Health Canada beta-lactoglobulin assessment
• C10 — FAO 2013 protein quality
• C11 — EU authorized protein claims
• C12 — FDA allergy guidance
• C13 — Health Canada pea allergy
• C14 — NIDDK lactose intolerance
• C15 — Specified baker's yeast protein rule
• C16 — Levothyroxine label May 2026
• C17 — Tranylcypromine label
• C18 — Pinckaers 2024 disclosures
• C19 — Angel nutrition fund
• C20 — Arla ownership and country
• C21 — Lesaffre ownership disclosure
• C22 — FDA supplement rules
• C23 — FSSAI official portal
• C24 — FDA funding and restricted user fees

One daily research roundup

Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.

Email address

Leave empty

I want Pure City Research daily digests and have read the privacy policy.Get the daily digest

Confirm through your inbox. Unsubscribe anytime. Research only; Shop updates have a separate signup. Please do not send health information.